🔗 Share this article

As America undertakes historic revisions to its immunization recommendations, a particular individual has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who first made her name by casting doubt on coronavirus vaccinations throughout the pandemic and has focused upon potential fatalities following Covid immunization in her brief tenure at the FDA.

Planned Shifts to Pediatric Immunization Schedule

Agency leaders were set to reveal major revisions to the pediatric vaccination calendar recently, synchronizing the US with the Danish national calendar, it is understood – a significant shift that would put the US out of step with many the global community with insufficient data for public health gain. The planned update has been delayed until the next year.

In place of the director of the vaccine center, Dr. Høeg is scheduled to speak at the meeting. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the office this year.

A Shift at the Regulatory Body

This interim role might represent a closer partnership between the pharmaceutical and biologics branches as Dr. Høeg and Prasad strengthen their influence at the agency – and it points to a greater focus upon dismantling previously authorized immunizations at the FDA.

Høeg has frequently advocated for halting some pediatric immunization guidelines in the US so as to align more in line with Denmark, a country with nationalized medicine and a population roughly the population of Wisconsin’s.

In her initial comments, she has kept her attention on vaccination policy – traditionally the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Doubts Over Expertise

The appointee has little discernible background in medication creation, approval processes or leadership, which has been customary for past directors of the biologics center. She has been employed at the FDA as a top consultant to the FDA chief and the vaccine center since spring.

“She doesn’t seem to have any of the qualifications” for leading the CDER, remarked Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in managing a large organization. She is not an expert in pharmaceutical oversight.”

Former heads of CBER would “be deeply familiar with regulatory frameworks and the science of medication creation”, said Janet Woodcock. “Frankly, she has not acquired the sort of resume that former directors who ran the center have had.”

The drug center has an vast workload at the FDA, the former commissioner stated.

“Everybody just zeroes in on the new drug program, but the off-patent medication office clears numerous generic medications. There’s a biologic copycat branch, OTC medication office and more, and each of these have to be looked after,” Dr. Woodcock said. “The thing you overlook, that is the part that I always told people is going to come back to haunt you.”

There is also, a significant management element to the position, which supervises over 5,000 personnel. “It is a huge administrative position, if you do it right,” Woodcock added.

Official Statement and Contentious Policies

When asked about questions about Høeg’s qualifications and whether this assignment signifies increased cooperation among regulatory chiefs on immunizations, a press secretary stated that the “concerns rely on inaccurate premises”.

“This background aligns with the functions of her role,” the spokesperson said, citing the time Høeg spent advising the agency head on “pharmaceutical safety and approval science, including computational safety modeling and vaccine surveillance”.

As the temporary head, Høeg inherits the commissioner’s new priority voucher program, a contentious one-day drug-approval program that allegedly concerned her preceding directors. “By what process are these medications being picked for this fast-track system? Who takes the decisions?” Dr. Howard questioned. “There’s a lot of lack of transparency happening at the FDA right now.”

In general, he remarked, “the agency seems to be moving towards more relaxed oversight of pharmaceuticals, with the exception of shots.”

Documented Past Work on Vaccines

Concerning immunizations, Dr. Høeg has a more established, if troubling, past, some experts observe. She released a study using non-validated volunteer-provided data to assess the incidence of heart inflammation following COVID-19 immunization. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have altered data to imply Covid vaccines are more dangerous than they are.

Part of her “desired changes” for the incoming federal leadership featured changing guidelines for novel immunizations and halting “optional” vaccines, she said after the election on a audio program. At the FDA, Høeg has reportedly proposed preventing adolescent males from getting COVID-19 vaccines.

“She’s an complete ideologue who begins with her conclusions and reverse-engineers to fit the science in a highly deceptive, untruthful way,” Dr. Howard stated.

Gaining Influence and a “Campaign of Retribution”

Høeg became part of fellow dissenters, {like|